Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $17
Optimistic Buy Rating for Perspective Therapeutics Amid Strategic Clinical Developments and Strong Financial Position
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $10
Truist Financial Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)
Perspective Therapeutics Is Maintained at Buy by Truist Securities
Perspective Therapeutics Analyst Ratings
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Maintains Target Price $6
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $11 to $17
Promising Outlook for Perspective Therapeutics: Buy Rating Affirmed Amid Clinical Progress and Strong Financial Position
Perspective Therapeutics Is Maintained at Outperform by RBC Capital
Perspective Therapeutics Analyst Ratings
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target
Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX) and BioMarin Pharmaceutical (BMRN)
Scotiabank Sticks to Its Buy Rating for Perspective Therapeutics (CATX)
Perspective Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Perspective Therapeutics Analyst Ratings
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Promising Developments and Strategic Trial Design Justify Buy Rating for Perspective Therapeutics
H.C. Wainwright Initiates Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $10